Currently, allergic diseases are rapidly increasing, particularly in urban areas, and three out of 10 people suffer from allergic conditions such as bronchial asthma, atopic dermatitis and pollenosis. Their treatment is a major problem. Various anti-allergy drugs have been developed as preventive treatment, but their efficacy, reflecting the complicated nature of allergic diseases, is rather limited. Recently, leucotriene C 4 , D 4 and E 4 receptor antagonists (e.g. pranlukast) have reached the market and have attracted attention since they are more effective than conventional anti-allergy drugs.
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1) On the other hand, it has also been reported that leucotriene B 4 , which is not affected by leucotriene C 4 antagonists, is produced by mast cells and acidocytes and closely associated with allergic symptoms.
2) Accordingly, it is considered to be preferable to inhibit the activity of 5-lipoxygenase, a leucotriene producing enzyme, to control as far as possible the effect of leucotrienes which are intimately involved in the onset and evolution of allergic symptoms.
In fact, various 5-lipoxygenase inhibitors have been proposed as anti-allergy candidates.
3) However, although these candidate compounds exhibit very potent 5-lipoxygenase inhibiting action in vitro, they have poor anti-allergy activity in vivo and so their development has been terminated. Almost all the compounds having a strong 5-lipoxygenase inhibiting action contain a catechol moiety and compounds having a catechol moiety are rendered almost completely physiologically inactive due to metabolism by catechol O-methyl transferase (COMT) in the liver. 4) In this paper, we describe the synthesis of trimethylhydroquinone derivatives which do not have a catechol moiety, but exhibit anti-lipid peroxidative action, 5-lipoxygenase inhibition and anti-allergy activity following oral administration to rats.
Chemistry
The synthetic route to trimethylhydroquinone derivatives (9) is shown in Chart 1. 1-Diphenylmethylpiperazine (3) was prepared from chlorodiphenylmethane (1) and piperazine (2) under reflux with K 2 CO 3 . 5) Bromo-and chloro-derivatives (8) were obtained by the method of Taniguchi.
6) Trimethylhydroquinone (4) and the corresponding bromo-or chloro-alcohol (7) were refluxed in the presence of phosphomolybdic acid to yield compounds 8. 4-(5-Bromopentyloxy)-2,3,6-trimethylphenol (8d) was obtained by bromination 7) of 4-(5-hydroxypentyloxy)-2,3,6-trimethylphenol (6), prepared from 4 and pentamethyleneglycol (5) by the method of Taniguchi. 6) Compound 3 and compounds 8 were refluxed with K 2 CO 3 to yield compounds 9. Dihydrochloric acid salts (9 · 2HCl) were prepared from compounds 9 for use in the pharmacological assays.
Pharmacological Results and Discussion
The anti-lipid peroxidation activity in rat liver microsomes was assessed. Compounds 9 · 2HCl exhibited a concentration dependent inhibition of Fe 3ϩ -ADP induced lipid peroxidation in rat liver microsomes (Fig. 1 ). Among these, 9a · 2HCl (IC 50 ϭ7.9ϫ10
and 9e · 2HCl (1.2ϫ 10 Ϫ6 M) exhibited more potent inhibition than the antioxidant, butylhydroxytoluene (BHT), (2.7ϫ10 Ϫ6 M) which was used as a positive control. Active oxygen is released from eosinophils and neutrophils, and plays an important role in allergic inflammation. 8) Therefore, these compounds may be inhibiting the allergic action by acting on this pathway.
The inhibition by compounds 9 · 2HCl of 5-lipoxygenase was concentration dependent as far as RBL-1 cell 5-lipoxygenase ( Fig. 2) was concerned. Compounds 9c · 2HCl and 9d · 2HCl showed the most potent inhibitory activity (IC 50 ϭ 3.5ϫ10 Ϫ7 M), and this was a little lower than that of a positive control compound, nordihydroguaiaretic acid (NDGA), with a catechol moiety (1.7ϫ10 Ϫ7 M). We previously reported that hydroquinone monoalkyl ethers exhibited both anti-oxidative and inhibitory effects on 5-lipoxygenase. In a series of hydroquinone derivatives, the 2,3,6-trimethyl-4-O-alkyl hydroquinones were more potent than unsubstituted hydroquinone monoalkyl ethers. 9) Therefore, it was suggested that the trimethylhydroquinone moiety played a role in the activity of compounds 9 · 2HCl.
The anti-allergy action of compounds 9 · 2HCl was evaluated using a 48 h homologous passive cutaneous anaphylaxis (PCA) reaction employing an oral anti-allergy agent, tranilast, as a positive control. This compound is supposed to have almost the same efficacy in the PCA reaction in rats as the series of compounds described in this paper (Fig. 3) . As a result, compounds 9 · 2HCl showed anti-allergy activity even following oral administration (100 mg/kg p.o.) and compound 9b · 2HCl exhibited the highest inhibition (69%). The percentage inhibition by tranilast, compounds 9a · 2HCl, 9c · 2HCl, 9d · 2HCl, 9e · 2HCl, 9f · 2HCl and 9g · 2HCl was 34%, 15%, 58%, 53%, 57%, 56% and 41%, respectively. Because compounds 9 · 2HCl have a diphenylmethylpiperazine moiety similar to that of oxatomide, anti-histaminic agent, 10) there might have inhibited the PCA reaction by their anti-histaminic action. The compounds 9 · 2HCl, had no inhibitory effect on the degranulation of mast cells (data not shown). Unlike the 5-lipoxygenase inhibitors with a cathecol moiety, the compounds 9 · 2HCl exhibited in vivo activity as shown in the PCA reaction described above. This shows that these compounds would protect against the aggravation of allergic symptoms caused by leucotrienes, including leucotriene B 4 . In conclusion, a novel series of trimethylhydroquinone derivatives was synthesized and found to have anti-oxidative and anti-allergic effects. This suggests that they may be potential lead compounds for the development of new anti-allergy drugs.
Experimental
Melting points were measured on a BÜCHI 510 apparatus and are uncorrected. IR spectra were recorded on a JASCO FT/IR-5300 spectrometer by the diffuse reflection measurement method. NMR spectra were measured on a Varian Unity 200 or JEOL JNM-GX400 (200 MHz for 1 H and 50 MHz for 13 C or 400 MHz for 1 H and 100 MHz for 13 C) spectrometer in CDCl 3 solution with tetramethylsilane as an internal standerd. High resolution electron impact mass spectra (HR-EI-MS) were obtained on a JEOL JMS-HX100 spectrometer. Elemental analyses were recorded with a Perkin-Elmer 2400 C, H, N analyzer. Silica gel column chromatography was performed on Merck Kieselgel 60 (70-230 mesh).
1-Diphenylmethylpiperazine 5) (3) Chlorodiphenylmethane (1) (4.86 g, 24.0 mmol) and piperazine (2) (20.7 g, 240 mmol) were dissolved in 30 ml CH 3 CN. K 2 CO 3 (3.65 g, 26.4 mmol) was added to the solution. The mixture was heated under reflux for 24 h. After filtration, the filtrate was evaporated, dissolved in AcOEt, washed with water and brine, dried over anhydrous Na 2 SO 4 and evaporated. The residue was chromatographed on silica gel (hexane-EtOH-Et 3 N, 10 : 2 : 1) to afford 3 (5.9 g, 23.4 mmol, 98%) as a white powder, mp 114-116°C. IR cm 4-(5-Hydroxypentyloxy)-2,3,6-trimethylphenol (6) Trimethylhydroquinone (4) (1.00 g, 6.57 mmol) and pentamethyleneglycol (5) (2.05 g, 19.7 mmol) were dissolved in 20 ml toluene. Phosphomolybdic acid (Nacalai Tesque, Inc., 0.50 g) was added to the solution and the mixture was heated under reflux for 24 h. The mixture was filtered through celite and the filtrate was evaporated. The residue was chromatographed on silica gel (CHCl 3 -AcOEt, 5 : 1) and the product was recrystallized from pentanehexane to afford 6 (0. 4-(2-Bromoethoxy)-2,3,6-trimethylphenol (8a) 4 (10.0 g, 65.7 mmol) and 2-bromoethanol (7a) (16.4 g, 131 mmol) were dissolved in 40 ml toluene. Phosphomolybdic acid (1.92 g) was added to the solution and the mixture was heated under reflux for 24 h. The mixture was filtered through celite and the filtrate was evaporated. The residue was chromatographed on silica gel (benzene-hexane, 5 : 1) and the product was recrystallized from pentanehexane to afford 8a (8.0 g, 30.9 mmol, 47%) as colorless needles, mp 110- 4-(3-Bromopropyloxy)-2,3,6-trimethylphenol (8b) 4 (7.61 g, 50.0 mmol) and 3-bromo-1-propanol (7b) (6.95 g, 50.0 mmol) were dissolved in 40 ml toluene. Phosphomolybdic acid (1.00 g) was added to the solution and the mixture was heated under reflux for 24 h. The mixture was filtered through celite and the filtrate was evaporated. The residue was chromatographed on silica gel (hexane-AcOEt, 7 : 1) and the product was recrystallized from pentane-hexane to afford 8b (5.4 4-(4-Chlorobutoxy)-2,3,6 -trimethylphenol (8c) 4 (2.00 g, 13.1 mmol) and 4-chloro-1-butanol (7c) (4.30 g, 39.6 mmol) were dissolved in 20 ml toluene. Phosphomolybdic acid (1.00 g) was added to the solution and the mixture was heated under reflux for 24 h. The mixture was filtered through celite and the filtrate was evaporated. The residue was chromatographed on silica gel (hexane-AcOEt, 10 : 1) and the product was recrystallized from pentane-hexane to afford 8c (1. 4 4-(6-Chlorohexyloxy)-2,3,6-trimethylphenol (8e) 4 (8.00 g, 52.6 mmol) and 6-chloro-1-hexanol (7e) (21.6 g, 158 mmol) were dissolved in 40 ml toluene. Phosphomolybdic acid (1.00 g) was added to the solution and the mixture was heated under reflux for 24 h. The mixture was filtered through celite and the filtrate was evaporated. The residue was chromatographed on silica gel (hexane-AcOEt, 4 : 1) and the product was recrystallized from pentane-hexane to afford 8e (10.6 g, 39.1 mmol, 74%) as colorless needles, mp 48-49°C. IR cm and 8-bromo-1-octanol (7f) (3.30 g, 15.8 mmol) were dissolved in 20 ml toluene. Phosphomolybdic acid (0.50 g) was added to the solution and the mixture was heated under reflux for 24 h. The mixture was filtered through celite and the filtrate was evaporated. The residue was chromatographed on silica gel (benzene-hexane, 4 : 1) and the product was recrystallized from pentane-hexane to afford 8f (3.9 g, 11.4 mmol, 72%) as colorless needles, mp 47 4-[2-[4-(Diphenylmethyl)-1-piperazinyl]ethoxy]-2,3,6-trimethylphenol  (9a) 3 (0.97 g, 3.86 mmol) and 8a (1.00 g, 3. 86 mmol) were dissolved in 20 ml CH 3 CN. K 2 CO 3 (1.08 g, 7.81 mmol) was added to the solution and the mixture was heated under reflux for 24 h. After filtration, the filtrate was evaporated and chromatographed on silica gel (hexane-AcOEt, 2 : 1) to afford 9a (0. 12 mmol) and 8c (1.00 g, 4.12 mmol) were dissolved in 20 ml CH 3 CN. K 2 CO 3 (1.14 g, 8.25 mmol) was added to the solution and the mixture was heated under reflux for 24 h. After filtration, the filtrate was evaporated and chromatographed on silica gel (hexane-AcOEt, 2 : 1) to afford 9c (1.4 g, 3.05 mmol, 74%) as a brown amorphous powder. IR cm 53.8 (t), 59.0 (t), 69.5 (t), 76.6 (d), 112.6 (d), 120.9 (s), 124.3 (s) Synthesis of 9 · 2HCl A mixture of 9 and HCl (2 eq) in diethyl ether was stirred for 1 h on an ice bath. The solvent were evaporated and the residue were recrystallized from EtOH-diethyl ether to afford 9a · 2HCl (74%), 9b · 2HCl (74%), 9c · 2HCl (92%), 9d · 2HCl (66%), 9e · 2HCl (83%), 9f · 2HCl (72%) and 9g · 2HCl (81%), respectively. 9a · 2HCl: mp 189-191°C (dec. -ADP Induced NADPH Dependent Lipid Peroxidation in Rat Liver Microsomes This experiment was carried out as described in a previous report.
9)
Measurement of RBL-1 Cell 5-Lipoxygenase Activity This experiment was carried out as described in a previous report.
11)
Effects on 48 h Homologous PCA Reaction in Rats This experiment was carried out according to the method of Koda et al. 12) Dinitrophenylated bovine serum albumin (DNP-BSA) and rat anti-DNP-BSA serum were prepared and used as antigen and antiserum, respectively. The dorsum of a Wistar-strain male rat weighting about 200 g, was shaved and 0.1 ml of an antiserum, with a 48 h homologous PCA strength of 1 : 128-1 : 256 diluted with physiological saline, was injected into the dorsum intracutaneously. After 48 h, 1 ml 0.5% Evans blue physiological saline, containing DNP-BSA equivalent to 1 mg protein, was injected into the caudal vein. After 30 min, the rat was killed by exsanguination and the pigment freckle generated on the back skin was cut out and the amount of transudate pigment was determined. To do this, the cut out skin was put in a test tube, 1 ml 1 N KOH was added and allowed to stand overnight at 37°C to elute the pigment and then 9 ml of a mixture of acetone and 0.6 N phosphoric acid (mixed at 13 : 5) was added with shaking. The insoluble substances were removed by centrifugation at 1500ϫg for 15 min, and the absorbence of the supernatant was measured at 620 nm to determine the amount of pigment. The specimen was suspended in 0.2% carboxymethyl cellulose sodium salt, and given orally to the rat, in dose of 0.5 ml per 100 g body weight, 2 h before antigen administration.
